The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice?

Jordi Remon, Lizza E.L. Hendriks, Martin Reck

Résultats de recherche: Contribution à un journal › Editorial

1 Citation (Scopus)

langue originale	Anglais
Pages (de - à)	1176-1179
Nombre de pages	4
journal	Journal of Clinical Oncology
Volume	41
Numéro de publication	6
Les DOIs	https://doi.org/10.1200/JCO.22.01737
état	Publié - 20 févr. 2023

Accès au document

@article{b0a6892d921947b0a2107642542c2ad3,

title = "The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice?",

author = "Jordi Remon and Hendriks, {Lizza E.L.} and Martin Reck",

year = "2023",

month = feb,

day = "20",

doi = "10.1200/JCO.22.01737",

language = "English",

volume = "41",

pages = "1176--1179",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

number = "6",

}

TY - JOUR

T1 - The POSEIDON Trial

T2 - Will Secondary End Points Change Our Clinical Practice?

AU - Remon, Jordi

AU - Hendriks, Lizza E.L.

AU - Reck, Martin

PY - 2023/2/20

Y1 - 2023/2/20

UR - http://www.scopus.com/inward/record.url?scp=85148249952&partnerID=8YFLogxK

U2 - 10.1200/JCO.22.01737

DO - 10.1200/JCO.22.01737

M3 - Editorial

C2 - 36331243

AN - SCOPUS:85148249952

SN - 0732-183X

VL - 41

SP - 1176

EP - 1179

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 6

ER -